EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration

Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim

Endocrinology and Metabolism · 31.08.2024 · 39 (4) · 579-589

DOI: 10.3803/enm.2024.1918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.08.2024. Verfasst von Meihua Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Changes in thyrotropin receptor antibody (TRAb) levels are associated with the clinical outcomes of Graves’ hyperthyroidism. However, the effects of the patterns of TRAb changes on patient prognosis according to the treatment duration of antithyroid drugs (ATDs) are not well established.

Methods

In this retrospective cohort study, 1,235 patients with Graves’ hyperthyroidism who were treated with ATDs for more than 12 months were included. Patients were divided into two groups according to treatment duration: group 1 (12–24 months) and group 2 (>24 months). Risk prediction models comprising age, sex, and either TRAb levels at ATD withdrawal (model A) or patterns of TRAb changes (model B) were compared.

Results

The median treatment duration in groups 1 (n=667, 54%) and 2 (n=568, 46%) was 17.3 and 37.1 months, respectively. The recurrence rate was significantly higher in group 2 (47.9%) than in group 1 (41.4%, P=0.025). Group 2 had significantly more goiter, thyroid eye disease, and fluctuating and smoldering type of TRAb pattern compared with group 1 (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseAntithyroid AgentsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedPrognosisRecurrenceDuration of TherapyImmunoglobulins, Thyroid-StimulatingRisk AssessmentRisk Factors

Stichwörter der Autor:innen

Antithyroid drugGraves hyperthyroidismRecurrenceRisk modelThyrotropin receptor antibody

Substanzen

Antithyroid AgentsImmunoglobulins, Thyroid-Stimulating

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Jin, M., Kim, C. A., Jeon, M. J., Kim, W. B., Kim, T. Y., & Kim, W. G. (2024). Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration. Endocrinology and Metabolism, 39(4), 579-589. https://doi.org/10.3803/enm.2024.1918

Vancouver

Jin M, Kim CA, Jeon MJ, Kim WB, Kim TY, Kim WG. Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration. Endocrinology and Metabolism. 2024;39(4):579-589. doi:10.3803/enm.2024.1918

BibTeX
@article{Jin2024,
  author = {Jin, Meihua and Kim, Chae A and Jeon, Min Ji and Kim, Won Bae and Kim, Tae Yong and Kim, Won Gu},
  title = {Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  volume = {39},
  number = {4},
  pages = {579--589},
  doi = {10.3803/enm.2024.1918}
}
Kostenlos starten →